Ophthalmology

Anti-VEGF intravitreal injection is the standard of care for patients with neovascular age-related macular degeneration or wet AMD. However, despite effective treatment options, many patients with wet AMD do not receive the recommended number of…

Although anti-VEGF therapy has revolutionized care for wet age-related macular degeneration (AMD), real-world analyses have shown limited improvement in visual acuity over time, largely due to treatment burden. However, several pipeline therapies could reduce the…

In the United States, women are more at risk than men of developing a serious eye disease and vision impairment, and wet age-related macular degeneration (AMD) is no exception. While wet AMD is still prevalent…

As wet age-related macular degeneration (AMD) progresses, choroidal thickening is hypothesized to occur. However, some studies also report choroidal thinning in eyes with wet AMD. This study, published in QJM: An International Journal of Medicine, sought…

Anti-VEGF intravitreal injections are used to treat wet age-related macular degeneration (AMD). This meta-analysis, published in Ophthalmic Research, examined the available research on the genetic polymorphism of ARMS2 A69S conferring susceptibility to AMD with response to…

Aflibercept is an anti-VEGF treatment used to treat wet age-related macular degeneration (AMD). However, patient response to aflibercept and other anti-VEGF treatments can vary. This prospective study, published in Photodiagnosis and Photodynamic Therapy, analyzed the anatomical…

Despite the use of anti-VEGF treatment for wet age-related macular degeneration (AMD), the relationship between anti-VEGFs and retinal atrophy remains inconclusive. This case series study, published in the European Journal of Ophthalmology, analyzed 13 eyes from…